Complexity of enzyme release during XXXX in a controlled study with early @entity594 treatment.

@entity1 @entity583 @entity594
Fifty-seven consecutive @entity1 with @entity583 ( @entity583 ), admitted to a coronary care unit (CCU) within 6 h from onset of symptoms were included in the study and randomly allocated to @entity594 treatment or placebo. The 23 @entity1 in the treatment group received 10 mg @entity594 orally at the onset of the study, after 30 min, and then every 6 h. Placebo was given to the 34 @entity1 in the control group. The study was double blind. Serum time-activity curves for creatine-kinase-MB (CK-MB) and myoglobin (MG) were established from frequent determinations. The two @entity1 groups did not differ significantly regarding average cumulative MG and CK-MB release. In both groups the range was wide, with the largest maximal individual release about 30 times larger than the smallest. In most @entity1 the enzyme release occurred stepwise, resulting in two or more separate peaks. In the treatment group significantly fewer @entity1 had multiple peaks of MG (P less than 0.05) and CK-MB (P less than 0.025) release. The initial peaks had a longer duration in the treatment group and total release tended to stop earlier. In the control group a highly significant correlation between cumulative MG and CK-MB release was obtained, while in the treatment group no such correlation was observed. In conclusion, oral administration of @entity594 during @entity583 appears to influence the pattern of enzyme release, although no effect on the total cumulative release could be demonstrated.
